Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1045 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Ashland acquires ISP for $3.2bn

As part of this acquisition, ISP will be merged into Ashland Aqualon Functional Ingredients commercial unit and the combined unit will be known as Ashland Specialty Ingredients. Ashland

FDA approves Apricus OTC anti-itch drug

Hydrocortisone-D, which uses the company’s proprietary drug delivery technology NexACT, combines hydrocortisone with DDAIP. The active ingredient in the cleared OTC drug, hydrocortisone, is an already approved anti-itch

Merck names new president for Animal Health unit

Merck Animal Health provides veterinarians, farmers, pet owners and governments a range of veterinary pharmaceuticals, vaccines and health management solutions. DeLuca worked as the chief financial officer of

Onset introduces HylatopicPlus Cream

The product is a prescription only medicine which protects against irritants and excessive water loss through the skin. HylatopicPlus Cream helps alleviate dry, waxy skin by maintaining a

Seattle Genetics starts Phase II Adcetris trial

The trial will also evaluate patients with diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. The trial will investigate the antitumor activity, duration

Fuji Xerox selects Extedo eCTDmanager Suite

Extedo operates in the following markets for human, veterinary and crop protection – life sciences, including pharmaceutical, biotech and biopharma, generics, homeopathics and medical devices, healthcare and public